Heilongjiang ZBD Pharmaceutical Co Ltd (603567) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.039x

Based on the latest financial reports, Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥283.54 Million ≈ $41.49 Million USD) by net assets (CN¥7.29 Billion ≈ $1.07 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Heilongjiang ZBD Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Heilongjiang ZBD Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Heilongjiang ZBD Pharmaceutical Co Ltd (603567) financial obligations for a breakdown of total debt and financial obligations.

Heilongjiang ZBD Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Heilongjiang ZBD Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
0.076x
Dongfeng Electronic Technology Co Ltd
SHG:600081
0.064x
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
N/A
AcadeMedia AB (publ)
ST:ACAD
0.200x
Chongqing Wangbian Electric (Group) Corp. Ltd.
SHG:603191
N/A
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
-0.019x
Dongguan Kingsun Optoelectronic Co Ltd
SHE:002638
-0.001x
Shenzhen Sunmoon Microelectronics Co. Ltd. A
SHG:688699
0.007x

Annual Cash Flow Conversion Efficiency for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Heilongjiang ZBD Pharmaceutical Co Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥8.29 Billion
≈ $1.21 Billion
CN¥164.31 Million
≈ $24.04 Million
0.020x +134.80%
2023-12-31 CN¥8.04 Billion
≈ $1.18 Billion
CN¥-457.90 Million
≈ $-67.00 Million
-0.057x -23.85%
2022-12-31 CN¥7.11 Billion
≈ $1.04 Billion
CN¥-326.79 Million
≈ $-47.82 Million
-0.046x +25.28%
2021-12-31 CN¥7.05 Billion
≈ $1.03 Billion
CN¥-433.94 Million
≈ $-63.50 Million
-0.062x -318.25%
2020-12-31 CN¥5.50 Billion
≈ $805.28 Million
CN¥155.18 Million
≈ $22.71 Million
0.028x -32.99%
2019-12-31 CN¥5.25 Billion
≈ $768.26 Million
CN¥220.92 Million
≈ $32.33 Million
0.042x -42.93%
2018-12-31 CN¥4.98 Billion
≈ $729.21 Million
CN¥367.40 Million
≈ $53.76 Million
0.074x -59.57%
2017-12-31 CN¥4.68 Billion
≈ $684.71 Million
CN¥853.19 Million
≈ $124.85 Million
0.182x +4862.02%
2016-12-31 CN¥4.31 Billion
≈ $630.20 Million
CN¥15.83 Million
≈ $2.32 Million
0.004x +104.52%
2015-12-31 CN¥3.98 Billion
≈ $582.63 Million
CN¥-323.90 Million
≈ $-47.40 Million
-0.081x -145.75%
2014-12-31 CN¥2.17 Billion
≈ $317.92 Million
CN¥386.32 Million
≈ $56.53 Million
0.178x +77.83%
2013-12-31 CN¥1.75 Billion
≈ $255.64 Million
CN¥174.68 Million
≈ $25.56 Million
0.100x -14.48%
2012-12-31 CN¥1.32 Billion
≈ $193.04 Million
CN¥154.25 Million
≈ $22.57 Million
0.117x +3.07%
2011-12-31 CN¥923.09 Million
≈ $135.08 Million
CN¥104.71 Million
≈ $15.32 Million
0.113x --

About Heilongjiang ZBD Pharmaceutical Co Ltd

SHG:603567 China Drug Manufacturers - Specialty & Generic
Market Cap
$992.80 Million
CN¥6.78 Billion CNY
Market Cap Rank
#9187 Global
#2483 in China
Share Price
CN¥7.21
Change (1 day)
+1.84%
52-Week Range
CN¥6.57 - CN¥13.15
All Time High
CN¥28.17
About

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.